Until the advent of immune-checkpoint inhibitors (ICIs), metastatic urothelial carcinoma (mUC) has remained an aggressive disease with few treatment improvements. Cisplatin-based combinations are the standard-of-care first-line option for “fit” (able to receive cisplatin) patients and have remained so for the last 3 decades.1,2 However, this therapeutic scenario might soon change if any of the ongoing phase 3 clinical trials combining ICIs with other immunotherapies or with chemotherapy vs standard-of-care chemotherapy as first-line therapy demonstrate a survival advantage of the ICI combination therapy.
Bellmunt J, Rodriguez-Vida A. Treatment of Metastatic Urothelial Cancer in 2018. JAMA Oncol. 2019;5(6):904–905. doi:10.1001/jamaoncol.2019.0182
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.